文献速递乳腺外科

BRCA突变人群预防性保留乳头乳房切除术的肿瘤学安全性:多中心研究

Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
PubMed 文献 · JAMA Surg · 2018-01-01

该多中心回顾性队列研究纳入9家机构1968至2013年间346例BRCA突变患者的548例预防性保留乳头乳房切除术(NSM),中位随访34个月,未观察到同侧乳腺癌发生,而风险模型预期约22例新发原发性乳腺癌,差异显著(P < .001),提示NSM在BRCA人群中具有高度预防作用。

要点

  • BRCA突变患者预防性NSM后中位随访34个月无同侧乳腺癌发生。
  • 风险模型预期未行NSM约22例新发乳腺癌,实际观察为零,差异显著(P < .001)。
  • NSM可作为合适BRCA突变患者的降低乳腺癌风险策略,但随访时间仍较短。

核心结论

  • 在BRCA突变人群中,保留乳头乳房切除术对乳腺癌具有高度预防作用,可作为合适的BRCA突变患者的降低乳腺癌风险策略。

研究设计与样本

  • 多中心回顾性队列研究,回顾9家机构1968至2013年间BRCA突变患者的预防性NSM结局,共纳入346例患者的548例预防性NSM。

主要发现

  • 中位随访34个月、平均随访56个月,预防性NSM后未发生同侧乳腺癌,接受双侧降低风险NSM的患者均未发生乳腺癌。
  • 采用BRCA1/2突变携带者风险模型,未行预防性NSM时预期约22例新发原发性乳腺癌,预防性NSM显著减少乳腺癌事件(观察事件与预期事件比较,P < .001)。

关键数值与推荐

  • 中位NSM年龄41岁(四分位距34.5-47.5岁)。
  • 双侧预防性NSM 202例(58.4%),单侧降低风险NSM 144例(41.6%,对侧乳腺癌)。
  • BRCA1突变201例,BRCA2突变145例。

临床怎么用

  • 对合适的BRCA突变患者,可将保留乳头乳房切除术作为降低乳腺癌风险的手术策略提供。

局限性

  • 随访时间仍相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nipple-sparing mastectomy (NSM) offers superior cosmetic outcomes and has been gaining wide acceptance; however, its role among patients with BRCA mutations remains controversial. OBJECTIVE: To report on the oncologic safety of NSM and provide evidence-based data to patients and health care professionals regarding preservation of the nipple-areolar complex during a risk-reducing mastectomy in a population with BRCA mutations. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively reviewed the outcomes of 9 institutions' experience with prophylactic NSM from 1968 to 2013 in a cohort of patients with BRCA mutations. Patients with breast cancer were included if they underwent contralateral risk-reducing mastectomy; however, only the prophylactic side was considered in the analysis. Patients found to have an occult primary breast cancer at the time of risk-reducing mastectomy, those having variant(s) of unknown significance, and those undergoing free nipple grafts were excluded. MAIN OUTCOMES AND MEASURES: The primary outcome measure was development of a new breast cancer after risk-reducing NSM. Three reference data sources were used to model the expected number of events, and this was compared with our observed number of events. RESULTS: A total of 548 risk-reducing NSMs in 346 patients were performed at 9 institutions. The median age at NSM was 41 years (interquartile range, 34.5-47.5 years). Bilateral prophylactic NSMs were performed in 202 patients (58.4%), and 144 patients (41.6%) underwent a unilateral risk-reducing NSM secondary to cancer in the contralateral breast. Overall, 201 patients with BRCA1 mutations and 145 with BRCA2 mutations were included. With median and mean follow-up of 34 and 56 months, respectively, no ipsilateral breast cancers occurred after prophylactic NSM. Breast cancer did not develop in any patients undergoing bilateral risk-reducing NSMs. Using risk models for BRCA1/2 mutation carriers, approximately 22 new primary breast cancers were expected without prophylactic NSM. Prophylactic NSM resulted in a significant reduction in breast cancer events (test of observed vs expected events, P < .001). CONCLUSIONS AND RELEVANCE: Nipple-sparing mastectomies are highly preventive against breast cancer in a BRCA population. Although the follow-up remains relatively short, NSM should be offered as a breast cancer risk-reducing strategy to appropriate patients with BRCA mutations.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Jakub JW, Peled AW, Gray RJ, et al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg. 2018. PMID: 28903167. doi:10.1001/jamasurg.2017.3422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。